Biostar Pharmaceuticals, the Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, has appointed Deyin ‘Bill’ Chen as chief financial officer (CFO). Chen replaces Elaine Zhao, who resigned.
Chen brings more than 13 years of multinational and Big 4 accounting experiences to Biostar. His expertise includes financial management, financing transactions, corporate governance and investor relations. Most recently, Chen was an independent advisor engaged in local renminbi (RMB) private equity (PE) fundraising and providing merger and acquisition (M&A) and PE advisory and due diligence services. Prior to that, he was a partner of Trenwith Securities, where he was engaged in and executed cross-border equity financing for various Chinese companies. He was also a senior business advisor of Ernst & Young and a senior financial advisor of IBM Global Services. From 1997 to 2000, Chen was the CFO for China Operations of Ashland.
Chen graduated with a Bachelor’s degree in Nuclear Physics from Fudan University, and MSc degree in Nuclear Engineering and Accountancy from University of Cincinnati. He also holds a MBA degree from York University.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.